"Dr. Pablo Lapuerta has 25 years of experience in the biotech industry and a track record of successful drug approvals including Xermelo, Inpefa, Abilify, and Avalide. He was previously Chief Medical Officer at Lexicon Therapeutics and Vice President of Clinical Development at Bristol-Myers Squibb. His work has been published in leading scientific journals including the New England Journal of Medicine. Dr. Lapuerta holds an MD from Harvard Medical School and a Bachelor’s degree in Biology from Harvard College where he graduated Summa Cum Laude. "